Second-line cannabis therapy in patients with epilepsy

Area of Science:

• Neurology
• Pharmacology

Background:

• Marijuana-based therapies (MBTs) show promise for reducing seizure frequency in severe, drug-resistant epilepsy (DRE).
• Pharmaceutical-grade cannabidiol (Epidiolex®) is FDA-approved for specific epilepsy syndromes, but the efficacy of switching MBT formulations is unclear.

Purpose of the Study:

• To determine if switching to an alternative marijuana-based therapy (MBT) formulation reduces seizure frequency in patients with drug-resistant epilepsy (DRE) who did not respond to an initial MBT.
• To investigate the impact of a second MBT on the side effect profile.

Main Methods:

• Retrospective chart review of 30 patients (≥2 years old) with DRE who used at least two different MBT formulations.
• Data collected included demographics, epilepsy history, medication details, seizure counts, and side effects.
• Analysis focused on seizure frequency changes, side effect profiles, and predictors of treatment response.

Main Results:

• No significant change in seizure frequency was observed from baseline to after the first MBT and after the second MBT (p=0.4).
• Patients with higher baseline seizure frequencies were more likely to respond to a second MBT (p=0.03).
• Increased seizure frequency was associated with experiencing side effects after a second MBT (p=0.04).

Conclusions:

• Switching to a second marijuana-based therapy (MBT) formulation is unlikely to significantly reduce seizure frequency in patients with drug-resistant epilepsy (DRE).
• Higher baseline seizure frequency may predict a response to a second MBT, but this is accompanied by a greater risk of side effects.
• Clinicians should consider alternative therapy classes rather than sequential MBT trials if the initial treatment fails.